Bridging the Gap: Immunotherapy in Progressive Multifocal Leukoencephalopathy: A New Hope?

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Tous droits réservés
ID Serval
serval:BIB_C5F359B44943
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Bridging the Gap: Immunotherapy in Progressive Multifocal Leukoencephalopathy: A New Hope?
Périodique
Neurology
Auteur⸱e⸱s
Born T., Vassallo P., Golshayan D., Di Liberto G., Brouland J.P., Egervari K., Merkler D., Du Pasquier R.A., Bernard-Valnet R.
ISSN
1526-632X (Electronic)
ISSN-L
0028-3878
Statut éditorial
Publié
Date de publication
26/09/2023
Peer-reviewed
Oui
Volume
101
Numéro
13
Pages
e1382-e1386
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
Progressive multifocal leukoencephalopathy (PML) is a severe infection of the CNS occurring in immunocompromised individuals in which large demyelinating lesions are induced by polyomavirus JC (JCV). In the absence of effective antiviral treatment, control of the infection relies on restoring anti-JCV immunity. Thus, particularly in long-standing immunocompromising conditions such as organ transplantation, lymphoproliferative disorders, or idiopathic lymphopenia, new strategies to boost anti-JCV immune responses are needed. Here, we report the case of a patient developing PML in the context of kidney transplantation who received recombinant human interleukin 7 to foster immune responses against JCV. We give an overview of the immunologic mechanisms underlying the development of PML and immune restoration within the CNS after JCV infection. Immunotherapeutic strategies developed based on current understanding of the disease hold promise in managing patients with PML.
Mots-clé
Humans, Leukoencephalopathy, Progressive Multifocal/therapy, JC Virus, Immunotherapy, Kidney Transplantation, Immunocompromised Host
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/07/2023 12:16
Dernière modification de la notice
17/01/2024 7:12
Données d'usage